ZFYVE19 Polyclonal Antibody, Invitrogen™
Manufacturer: Thermo Scientific
Select a Size
| Pack Size | SKU | Availability | Price |
|---|---|---|---|
| Each of 1 | PIPA530855-Each-of-1 | In Stock | ₹ 46,591.50 |
PIPA530855 - Each of 1
In Stock
Quantity
1
Base Price: ₹ 46,591.50
GST (18%): ₹ 8,386.47
Total Price: ₹ 54,977.97
Antigen
ZFYVE19
Classification
Polyclonal
Conjugate
Unconjugated
Gene
ZFYVE19
Gene Alias
1500041L05Rik; abscission/NoCut checkpoint regulator; ANCHR; MLL partner containing FYVE domain; MPFYVE; Zfyve19; Zinc finger FYVE domain-containing protein 19; zinc finger FYVE-type containing 19; zinc finger, FYVE domain containing 19
Host Species
Rabbit
Purification Method
Antigen affinity chromatography
Regulatory Status
RUO
Gene ID (Entrez)
72008, 84936
Content And Storage
Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.
Form
Liquid
Applications
Western Blot
Concentration
1 mg/mL
Formulation
PBS with 1% BSA, 20% glycerol and 0.01% thimerosal; pH 7
Gene Accession No.
Q96K21, Q9DAZ9
Gene Symbols
ZFYVE19
Immunogen
Recombinant protein fragment corresponding to a region within amino acids 140 and 312 of Human ZFYVE19
Quantity
100 μL
Primary or Secondary
Primary
Target Species
Human, Mouse
Product Type
Antibody
Isotype
IgG
Related Products
Description
- Recommended positive controls: 293T, A431, HeLa, HepG2, NIH-3T3, BCL-1
- Predicted reactivity: Human (99%), Bovine (80%)
- Store product as a concentrated solution
- Centrifuge briefly prior to opening the vial
- Key regulator of abscission step in cytokinesis: part of the cytokinesis checkpoint, a process required to delay abscission to prevent both premature resolution of intercellular chromosome bridges and accumulation of DNA damage
- Together with CHMP4C, required to retain abscission-competent VPS4 (VPS4A and/or VPS4B) at the midbody ring until abscission checkpoint signaling is terminated at late cytokinesis
- Deactivation of AURKB results in dephosphorylation of CHMP4C followed by its dissociation from ZFYVE19/ANCHR and VPS4 and subsequent abscission.